FDA Approves Clinical Trials For Milatuzumab-Doxorubicin Combination – The U.S. Food and Drug Administration (FDA) has approved Immunomedics Inc.'s investigational new drug application for its milatuzumab-based treatment for multiple myeloma.  This drug has doxorubicin (Adriamycin), a chemotherapy drug, bound to milatuzumab, an antibody.  It will be studied in Phase 1/2 clinical trials to evaluate safety and tolerability of the drug in patients with persistent or recurring myeloma.  This drug is also undergoing preclinical studies for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. For more information, please see the Immunomedics press release.

IMF Patient And Family Seminar – On August 28-29 the International Myeloma Foundation (IMF) is holding its patient and family seminar in Edina, MN. The seminar includes many presentations by specialists, which focus on managing side effects, standard frontline therapy, and approaches to relapse treatment. For more information, please visit the IMF Web site.

For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.